Submit manuscript...
Journal of
eISSN: 2379-6359

Otolaryngology-ENT Research

Mini Review Volume 10 Issue 6

Nicotine replacement therapy: a treatment angle for oral diagnostician

Anusha Rangare Lakshman,1 Nilofer Halim,1 Chaithra Kalkur,1 Amithash RL,2 Apoorva Mithrananda,3 Sham Kishor Kannepady4

1Department of Oral Medicine and Radiology, Century International Institute of Dental Science and Research Centre, India
2MBBS, MS Orthopaedics, Consultant Orthopaedic Surgeon, India
3MBBS, MS Opthalmology, Consultant Opthalmologist, India
4Senior Lecturer, Division of Oral Diagnostics and Surgical Sciences, International Medical University, India

Correspondence: Anusha Rangare Lakshman, M.D.S, Reader, Department of Oral Medicine and Radiology, Century International Institute of Dental Science and Research Centre, Poinachi, Kasaragod–671541, Kerala, India

Received: July 23, 2018 | Published: November 23, 2018

Citation: Lakshman AR, Halim N, Kalkur C, et al. Nicotine replacement therapy: a treatment angle for oral diagnostician. J Otolaryngol ENT Res. 2018;10(6):362-366. DOI: 10.15406/joentr.2018.10.00382

Download PDF

Abstract

As an oral diagnostician, many of our patients we come across are mostly the potentially malignant disorder cases. Either it might be leukoplakia, nicotina stomatitis, oral submucous fibrosis, tobacco pouch keratosis. In each of this cases where habits are the prime factor for occurrence of the lesions intraorally, the first line of treatment is cessation of the habits. But practically speaking, we don’t spend much time about the cessation of the habits. As an oral diagnostician, it is our duty to motivate and educate the patient about the evil effects of the deleterious habits and need to follow up the patient and guide him to quit the habits. This article intends to highlight about one of the methods to stop the deleterious habit of smoking that is nicotine replacement therapy and therewith preventing the transformation of potentially malignant disorders into oral cancer.

Keywords: nicotine replacement therapy, potentially malignant disorders, oral cancer, smoking

Introduction

Introduction

Oral cancers have become very common tumors among the people mainly because of the tobacco habits addiction. Epidemiological studies show that the risk of developing oral cancer is five to nine times greater for smokers than for nonsmokers, and this risk may increase to as much as 17 times greater for extremely heavy smokers of 80 or more cigarettes per day.1 As an oral diagnostician, we come across day to day at least one lesion which is habit associated, it might be either smoking, smokeless tobacoo or gutka or pan chewing. In spite of educating the patients about the ill effects of all this deleterious habits, patient won’t quit the habits. So it is important for us find some alternative method to motivate and help the patient to stop habits. Nicotine replacement therapy (NRT) is one of the methods to quit the habit of smoking. This term is heard long time back but still we feel personally, the most of the general dentists are unaware about NRT and its dosing. We have tried to briefly enlighten about the NRT, its mechanism, various modes and its dosages which might guide the general dentists to use NRT regularly in their private practice and thereby prevent the transformation of premalignant lesions into oral carcinoma.

Ingredients of tobacco

Tobacco and its products are extremely toxic. Its smoke has at least 250 chemicals out of 7000, which are harmful and 69 are known carcinogens. Such as Stearic acid, Butane, Methanol, Acetic acid, Hexamine, Methane, Cadmium, Arsenic, Toluene, Ammonia, Carbon monoxide, and finally the main culprit, Nicotine, the addictive product of the tobacco, the role of which cannot be overlooked. Now talking about the smokeless form, 31 carcinogens have been identified till date. Like tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons (PAHs), benzo[a]pyrene, urethane, formaldehyde, acetaldehyde, nickel, arsenic and chromium.2

Tobacco associated oral lesions

The toxic components of tobacco either as smoke or chewing form, causes damage to the oral mucosa. The free radicals produced from these products penetrate the epithelium and causes damage to the oral structures. The heat generated by the smoking habit also causes damage to these oral structures. These even stimulate the melanocytes. The following Table 1 shows the list of oral lesions associated with tobacco habits.

The culprit: nicotine

Nicotine is the main active component of tobacco products leading to its addiction.3,4 It is the main alkaloid and the principal modulator with psychopharmacological effects.5 So, if we need to help the patient to quit the tobacco habits, we should have thorough knowledge about the neurochemical and psychopharmacological effects of nicotine.6

What is nicotine replacement therapy (NRT)?

NRT is replacing the harmful nicotine with the ‘clean’ or therapeutic nicotine. The ‘clean’ or ‘therapeutic’ nicotine is referred to as nicotine that is not associated with the harmful constituents found in tobacco smoke. So this NRT targets the patient in two aspects, firstly it helps in de-addiction, secondly the emotional aspects associated with it.7

Mechanism of action

NRT is assumed to help in release of neurochemical, dopamine from the nucleus accumbens, by stimulating the nicotinic receptors present in the ventral tegmental area of the brain. Not only it is effective centrally but its peripheral action also helps in reduction in nicotine withdrawal symptoms in regular smokers who abstain from smoking.8

It will not help to completely stop the habits, but helps to reduce to certain extent mainly because of the compromised nicotine delivery system. That means, none of the different delivery systems cannot reach high levels of nicotine in the arteries which is easily achieved during cigarette smoking. For medicinal products such as nasal spray or gum, inhalator, sublingual tablet, or lozenge achieve lower levels over a period of minutes and for transdermal patches, it’s in hours.

Different forms of NRT:

The different NRT products have been summarized in Table 2 with the dose, its uses, adverse effects and the precautions. Various available forms includes: gum, transdermal patch, nasal spray, oral inhaler, and tablet.9

How soon after waking do you smoke your first cigarette?

  1. Less than 5 minutes (3 points)
  2. 5 to 30 minutes (2 points)
  3. 31 to 60 minutes (1 point)
  4. More than 60 minutes (no points)

How many cigarettes do you smoke each day?

  1. More than 30 cigarettes (3 points)
  2. 21 to 30 cigarettes (2 points)
  3. 11 to 20 cigarettes (1 point)
  4. 1 to 10 cigarettes (no points)

Score

Nicotine dependence

5 or 6

Heavy

3 or 4

Moderate

2

Low

Acute dosing is reached using gum, nasal spray, oral inhalers and tablets which helps in general craving relief with immediate release of nicotine whereas the transdermal patch acts slowly with sustained release.10,11 Different formulations have different levels of efficacy with different rates of nicotine absorption. But the psychiatric counseling has an additive effect along with this formulations (Table 3).12

Side effects of the NRT

The symptoms of nicotine overdose includes nausea, salivation, abdominal pain, sweating, headache, and diarrhea, dizziness, delayed wound healing and weakness.25 At very high doses, it depresses neuronal activity whereas at low doses, it stimulates.23,24 It acute lethal dose of nicotine in 40–60 mg25 and it can lead to death at 500mg or more dosages, due to generalized blockade of respiration.23 But, at the prescribed dosages of NRT, there was no evidence of any life threatening problems.25,26

Little caution is required while prescribing these NRT’s in medically compromised patients like acute cardiovascular disease, pregnancy, or breast feeding. NRT is safe in stable cardiac disease, but caution is needed in unstable.8 It has been studied that the adverse effects of NRT during pregnancy has substantially lower risk compared to that of smoking.27

Sl no:

Oral lesion

Habits

Most commom Sites

1

Smoker’s melanosis

Smoking

Buccal mucosa + labial mucosa + gingiva

2

Nicotina stomatitis

Smoking

Palate

3

Tobacco pouch keratosis

Smokeless tobacco

Vestibule

4

Leukoplakia

Smoking + smokeless tobacco

Buccal mucosa + labial mucosa

5

Oral submucous fibrosis

smokeless tobacco

Buccal mucosa + labial mucosa + palate + uvula

6

Oral cancer

Smoking + smokeless tobacco

Buccal mucosa+ alveolar mucosa+ tongue

Table 1 Shows the list of oral lesions associated with tobacco habits

NRT
formulations

Available doses

Cautions / warning

Uses

Adverse events

Availability

Transdermal patches

5 mg, 10 mg, 15 mg doses worn over 16 hours 7 mg, 14 mg, 21 mg doses worn
over 24 hours

For smokers with insomnia and other sleep-related adverse events, the patches
should be removed before bedtime.

One daily on clean, unbroken skin; remove before bed
(16 h patch) or next morning (24 h); new patch, fresh site

Local skin reaction Insomnia

US FDA (OTC), MHRA (OTC)

Chewing gum

2 mg and 4 mg doses

Temporomandibular
joint disease Caution with
dentures Do not eat or drink 15 min before or
during use

Chew gum until taste is strong, then rest gum between gum and cheek; chew again when taste has faded. Try not to swallow excessively.

Mouth soreness,
Hiccups, Dyspepsia and Jaw ache

US FDA
(OTC)
MHRA
(OTC)

Sublingual
tablet

2 mg dose

Nicotine dependence,
insomnia

Rest under tongue
until dissolved

Mouth soreness

MHRA (Rx)

Lozenge

1mg, 2 mg and 4 mg doses

Do not eat or drink
15 minutes before or
during use One lozenge at a
time Limit 20 in 24 hours

Allow to dissolve in mouth (about 20–30 minutes), moving from side-to-side from time-to-time. Try
not to swallow excessively. Do not chew or swallow whole

Nausea/ Heartburn

US FDA
(OTC)
MHRA
(OTC)

Nicotine inhalation
Cartridge plus mouthpiece

Cartridge containing 10mg

May irritate
mouth/throat at first

Spray into the mouth, avoiding the lips. Do not inhale while
spraying. Use when cigarettes would usually be smoked or
if cravings emerge.
Do not swallow for a
few seconds after
spraying

Local
irritation
of mouth
and
throat

US FDA
(Rx)
MHRA (Rx)

Nicotine metered nasal spray

0.5mg dose/spray

Not for patients with
asthma
May cause
dependence

Take shallow puffs
approximately every 2 seconds or
alternatively take four puffs every minute. Continue for up to 30 minutes.

Nasal
irritation

US FDA
(Rx)
MHRA (Rx)

Electronic cigarette

 

May cause dependence

E-Cigarette vapor is drawn very slowly into mouth, then held there for a second or two. Then, it can be
inhaled if desired.
The vapor is then
expelled through the
mouth or nose.

Mouth and
airway
irritation,
chest pain,
and
palpitation
(15,16)

Untill now, it
is not
approved by
any agency

High dose nicotine
patches17

≥42 mg daily

Irritation at the patch
application site.
Sleep disturbances

One daily on clean,
unbroken
skin; remove before
bed

Headache,
cardiovasc
ular events,
asthenia,
dyspepsia,
myalgia,
and
vomiting

Untill now, it
is not
approved by
any agency

Combined
Patch +
acute forms
(nicotine
gum, spray,
lozenge, &
inhaler)18,19

Transdermal nicotine
doses of 7, 14, and 21 mg + dosage of any one
acute form

Nicotine dependence,
insomnia

Both patch and acute
nicotine forms should
be used parallel.

Mouth and
airway
irritation,
Nausea
and
vomiting

US FDA

Table 2 Different formulations of NRT.6,9,13,14

*US FDA: U S Food and Drug Administration; MHRA: Medicines and Healthcare products Regulatory

Rx, Prescription; OTC, Over the counter

Product

Dosage
Heavy - moderate

Dosage
Moderate – low

Gum

4mg (after the first 2 weeks you may prefer to use the 2mg gum)

- 2mg
- Use 1 piece per hour or 10-15 pieces per day

Patch

21mg/24 hour patch or 25mg/16 hour patch

- 14mg/24 hour path
- Use 1 patch daily

Nicotine mouth spray

Maximum of 4 sprays an hour/ 64 sprays a day

One or two sprays under the tongue or onto the inner cheek to relieve cravings

Lozenge

- 4mg lozenge
- 4mg & 2mg lozenges (9-15 per day)
- 1.5mg lozenge (9-20 per day)

2mg lozenge or 1.5mg lozenge

Inhalation

- 1 cartridge when you have urge to smoke or every 2-4 hours
- For best results use 3-6 cartridge for a day

 

Combination therapy

- 25mg/16 hour patch in combination with 2g gum or lozenge
- 21mg/24 hour patch in combination with 2mg gum or 2mg or 1.5mg lozenge
- Patch in combination with any intermittent form of NRT

 

Table 3 Guide for the selection of NRT product.7,20,21,22

Conclusion

NRT is one of the best options as a treatment for all habit associated lesions in the oral cavity. Most of the lesions respond well by cessation of the habits. And NRT helps the patient to quit the habit. As an oral diagnostician, we have to motivate and educate the patient about the use of NRT. This article briefly describes the dosages, forms and side-effects of NRT.

Acknowledgments

None.

Conflict of interest

No conflict of interest declared.

References

  1. Neville BW, Damm DD, Allen CM. Oral & maxillofacial pathology. 2nd ed. Phila., PA: Saunders; 2002;337–369.
  2. A guide for oral disease patients to quit tobacco use. Geneva: World Health Organization; 2017.
  3. Foulds J, Burke M, Steinberg M, et al. Advances in pharmacotherapy for tobacco dependence. Expert OpinEmerg Drugs. 2004;9(1):39–53.
  4. Kotlyar M, Hatsukami DK. Managing nicotine addiction. J Dent Educ. 2002;66(9):1061–1073.
  5. Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010.
  6. Wadgave U, Nagesh L. Nicotine Replacement Therapy: An Overview. Int J Health Sci (Qassim). 2016;10(3):425–435.
  7. Cancer council South Africa. Nicotine replacement therapy (NRT), 2016.
  8. Molyneux A. ABC of smoking cessation. Nicotine replacement therapy. BMJ. 2004;328(437):454–456.
  9. Henningfield JE, Fant RV, Buchhalter AR, et al. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005;55(5):281–99.
  10. Sweeney CT, Fant RV, Fagerstrom KO, et al. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs. 2001;15(6):453–467.
  11. Fagerstrom KO. Combined use of nicotine replacement products. Health Values 1994;18:15–20.
  12. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA. 2000;283(24):3244–3254.
  13. Yildiz D. Nicotine, its metabolism and an overview of its biological effects. Toxicon. 2004;43(6):619–632.
  14. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med. 2008;35(2):158–176.
  15. Hajek P, Etter JF, Benowitz N, et al. Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction. 2014;109(11):1801–1810.
  16. Cantrell FL. Adverse effects of e-cigarette exposures. Journal of community health. 2014;39(3):614–616.
  17. Brokowski L, Chen J, Tanner S. High-dose transdermal nicotine replacement for tobacco cessation. Am J Health Syst Pharm. 2014.15;71(8):634–638.
  18. Recommendations for Use of Combination Therapy in Tobacco Use Cessation.2016.
  19. US Department of Veteran affairs. 2015.
  20. Action on Smoking and Health Australia. Guidelines for Healthcare Professionals on using Nicotine Replacement Therapy for smokers not yet ready to stop smoking. Sydney: Action on Smoking and Health Australia. 2007.
  21. Zwar N, Richmond R, Borland R, et al. Smoking cessation pharmacotherapy: an update for health professionals. Melbourne: The Royal Australian College of General Practitioners. 2007, p. 16–18.
  22. Zwar N, Richmond R, Borland R, et al. Smoking Cessation Guidelines for Australian General Practice. Practice Handbook. Canberra: Australian Government, Department of Health and Aging. 2004.
  23. Meyer B. How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self experiments in the nineteenth century. Arch Toxicol. 2014;88(1):5–7.
  24. Karl F. Nicotine: Pharmacology, Toxicity and Therapeutic use. J Smok Cessat. 2014;9:53–59.
  25. Lavelle C, Birek C, Scott DA. Are nicotine replacement strategies to facilitate smoking cessation safe? J Can Dent Assoc. 2003;69(9):592–597.
  26. Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009;2;338:b1024.
  27. Osadchy A, Kazmin A, Koren G. Nicotine replacement therapy during pregnancy: recommended or not recommended? J Obstet Gynaecol Can. 2009;31(8):744–747.
Creative Commons Attribution License

©2018 Lakshman, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.